The next chapter in regenerative medicine for osteoarthritis: From real-world evidence to regulatory shifts

The next chapter in regenerative medicine for osteoarthritis: From real-world evidence to regulatory shifts Osteoarthritis (OA) remains one of the leading causes of disability worldwide, yet the therapeutic landscape is evolving faster than ever. In a previous article, I outlined how stromal vascular fraction (SVF), exosomes, platelet-rich fibrin (PRF), and early findings in blood-derived stem cells were reshaping the field of regenerative medicine. Since then, two new clinical and translational studies have provided important real-world evidence, helping to move the discussion from theory toward practice. Exosomes, nanosized extracellular vesicles secreted by stem cells, have attracted increasing attention for their ability to modulate inflammation, stimulate repair, and enhance tissue homeostasis without the risks of uncontrolled differentiation. While early case series suggested encouraging clinical results, questions remained about long-term safety.